Supplementary Table 1. miRNA expression profiles in EPF vs CPF
Downregulated miRNAs
miRNA / P-value / Fold-Change
hsa-miR-3621 / 1.23E-02 / -4.736
hsa-miR-3180-3p / 3.23E-02 / -3.664
hsa-miR-1231 / 9.41E-03 / -3.513
hsa-miR-4492 / 4.49E-02 / -3.481
hsa-miR-1343-5p / 4.66E-02 / -3.418
hsa-miR-1909-3p / 4.70E-02 / -3.396
hsa-miR-4632-5p / 2.35E-02 / -3.312
hsa-miR-3937 / 2.58E-03 / -3.251
hsa-miR-6722-3p / 2.64E-02 / -3.188
hsa-miR-3141 / 2.95E-02 / -3.130
hsa-miR-4486 / 1.30E-02 / -3.124
hsa-miR-4695-5p / 3.81E-02 / -3.097
hsa-miR-6779-5p / 1.37E-02 / -3.040
hsa-miR-6789-5p / 2.61E-02 / -2.896
hsa-miR-5189-5p / 1.28E-02 / -2.795
hsa-miR-6816-5p / 4.33E-02 / -2.719
hsa-miR-6769b-5p / 4.35E-02 / -2.605
hsa-miR-149-3p / 3.93E-02 / -2.481
hsa-miR-3196 / 2.83E-02 / -2.455
hsa-miR-6858-5p / 3.47E-02 / -2.421
hsa-miR-4488 / 1.99E-02 / -2.405
hsa-miR-8089 / 3.70E-02 / -2.281
hsa-miR-4690-5p / 2.78E-02 / -2.267
hsa-miR-1229-5p / 3.98E-02 / -2.234
hsa-miR-1228-5p / 2.41E-02 / -2.185
hsa-miR-6846-5p / 1.72E-02 / -2.114
hsa-miR-4707-5p / 2.77E-02 / -2.108
hsa-miR-3656 / 4.39E-02 / -2.086
hsa-miR-7108-5p / 2.59E-02 / -2.041
hsa-miR-8072 / 4.17E-02 / -2.018
hsa-miR-6860 / 2.15E-02 / -1.982
hsa-miR-6132 / 3.96E-02 / -1.912
hsa-miR-139-3p / 3.33E-03 / -1.840
hsa-miR-6088 / 4.40E-02 / -1.815
hsa-miR-6799-5p / 3.62E-02 / -1.813
hsa-miR-1237-5p / 4.54E-02 / -1.788
hsa-miR-6753-5p / 1.15E-02 / -1.745
hsa-miR-4685-5p / 4.77E-02 / -1.728
hsa-miR-3147 / 3.63E-02 / -1.592
hsa-miR-3188 / 2.22E-02 / -1.536
hsa-miR-6735-5p / 3.86E-02 / -1.514
hsa-miR-7114-5p / 3.13E-02 / -1.500
hsa-miR-129-5p / 2.44E-03 / -1.483
hsa-miR-6736-5p / 3.38E-02 / -1.449
hsa-miR-4784 / 9.84E-03 / -1.442
hsa-miR-6840-3p / 1.97E-02 / -1.437
hsa-miR-1909-5p / 2.92E-02 / -1.433
hsa-miR-6165 / 6.90E-03 / -1.432
hsa-miR-6836-3p / 2.98E-02 / -1.428
hsa-miR-6738-5p / 3.22E-02 / -1.381
hsa-miR-6515-5p / 4.94E-02 / -1.371
hsa-miR-4746-3p / 3.99E-02 / -1.371
hsa-miR-6894-5p / 3.09E-02 / -1.362
hsa-miR-4667-3p / 2.58E-02 / -1.353
hsa-miR-7113-3p / 1.03E-02 / -1.335
hsa-miR-4793-5p / 2.23E-02 / -1.331
hsa-miR-6886-5p / 1.52E-02 / -1.328
hsa-miR-769-3p / 3.72E-02 / -1.325
hsa-miR-570-3p / 3.72E-02 / -1.318
hsa-miR-29c-3p / 4.36E-02 / -1.295
hsa-miR-6766-3p / 4.28E-02 / -1.293
hsa-miR-3974 / 6.82E-03 / -1.286
hsa-miR-4644 / 2.89E-02 / -1.283
hsa-miR-4450 / 2.30E-02 / -1.278
hsa-miR-623 / 2.14E-02 / -1.267
hsa-miR-514b-5p / 1.73E-02 / -1.266
hsa-miR-3689a-5p / 6.21E-03 / -1.258
hsa-miR-3689b-5p / 6.21E-03 / -1.258
hsa-miR-3689e / 6.21E-03 / -1.258
hsa-miR-6807-3p / 4.23E-03 / -1.255
hsa-miR-128-1-5p / 5.08E-03 / -1.253
hsa-miR-505-3p / 8.14E-03 / -1.246
hsa-miR-4257 / 8.02E-03 / -1.241
hsa-miR-3176 / 8.52E-03 / -1.240
hsa-miR-296-3p / 4.71E-02 / -1.237
hsa-miR-6884-5p / 3.87E-02 / -1.232
hsa-miR-181c-3p / 1.68E-02 / -1.227
hsa-miR-4509 / 3.79E-02 / -1.209
Upregulated miRNAs
miRNA / P-value / Fold-Change
hsa-miR-543 / 9.27E-03 / 1.201
hsa-miR-1303 / 4.12E-02 / 1.201
hsa-miR-1297 / 1.08E-02 / 1.202
hsa-miR-4681 / 1.31E-02 / 1.206
hsa-miR-4738-5p / 4.51E-02 / 1.211
hsa-miR-2681-3p / 4.87E-02 / 1.211
hsa-miR-103b / 2.61E-02 / 1.216
hsa-miR-2909 / 6.60E-03 / 1.217
hsa-miR-3191-3p / 3.65E-02 / 1.221
hsa-miR-6869-3p / 3.57E-02 / 1.222
hsa-miR-563 / 3.34E-02 / 1.222
hsa-miR-567 / 6.29E-03 / 1.226
hsa-miR-3529-3p / 1.32E-02 / 1.228
hsa-miR-518a-3p / 1.09E-02 / 1.228
hsa-miR-8061 / 2.78E-03 / 1.231
hsa-miR-4424 / 2.83E-02 / 1.232
hsa-miR-8057 / 1.22E-02 / 1.236
hsa-miR-4524a-3p / 2.73E-02 / 1.237
hsa-miR-194-5p / 1.70E-02 / 1.248
hsa-miR-6771-3p / 3.62E-02 / 1.253
hsa-miR-708-5p / 4.35E-02 / 1.253
hsa-miR-519d-5p / 1.66E-03 / 1.255
hsa-miR-935 / 1.21E-02 / 1.257
hsa-miR-3167 / 4.07E-02 / 1.259
hsa-miR-3121-5p / 9.16E-04 / 1.265
hsa-miR-4418 / 1.31E-02 / 1.265
hsa-miR-1296-5p / 2.18E-02 / 1.266
hsa-miR-3925-3p / 3.00E-02 / 1.274
hsa-miR-642b-5p / 3.95E-02 / 1.281
hsa-miR-652-5p / 2.90E-02 / 1.284
hsa-miR-216b-3p / 4.68E-02 / 1.285
hsa-miR-577 / 9.58E-03 / 1.289
hsa-miR-6770-3p / 4.12E-02 / 1.294
hsa-miR-6772-3p / 1.76E-02 / 1.296
hsa-miR-625-3p / 4.39E-02 / 1.297
hsa-miR-578 / 1.26E-02 / 1.304
hsa-miR-1207-3p / 3.12E-02 / 1.312
hsa-miR-3925-5p / 6.09E-03 / 1.342
hsa-miR-3115 / 2.39E-02 / 1.345
hsa-miR-140-5p / 2.86E-02 / 1.345
hsa-miR-320d / 4.87E-02 / 1.350
hsa-miR-519e-5p / 2.51E-03 / 1.384
hsa-miR-4429 / 2.63E-02 / 1.461
hsa-miR-23c / 4.25E-03 / 1.513
hsa-miR-106b-3p / 1.22E-02 / 1.689
hsa-miR-424-3p / 3.67E-02 / 2.009
hsa-miR-451a / 3.49E-02 / 4.172
hsa-miR-486-5p / 3.86E-02 / 8.235

126 mature miRNAs differentially expressed (p<0.05 and ≥1.2-fold change) (78 downregulated and 48 upregulated).

Shaded rows indicate miRNA selected for the validation phase.

miRNA / P-value / Fold-Change
hsa-miR-130a-3p / 0.7838 / -1.173
hsa-miR-150-5p / 0.5394 / 1.146
hsa-miR-185-5p / 0.1418 / 2.634
hsa-miR-195-5p / 0.8291 / 1.094

miRNAs also selected for the validation phase because of their potential targets involved in angiogenesis, proteolysis or endometriosis, although without statistically significant differences were observed in the array.